6 Recommendations for PBM Procurement and Rx Benefits Optimization

Why It Matters

These recommendations give employers a roadmap to curb escalating drug spend, satisfy new regulatory mandates, and fulfill fiduciary obligations in a tightening benefits market.

Key Takeaways

• Evaluate drug mix, not just unit cost.
• Prioritize biosimilars to curb specialty spend.
• Anticipate lower rebates due to Medicare price reforms.
• Monitor state/federal PBM regulatory changes.
• Leverage $0 generic programs for cost savings.

Pulse Analysis

The PBM landscape is undergoing a tectonic shift as legislation at both state and federal levels forces a move away from opaque pricing models toward greater transparency. Laws banning spread pricing, mandating full pass‑through of manufacturer revenue, and tightening reporting requirements are reshaping how PBMs negotiate discounts and rebates. For employers, this means the traditional reliance on high‑rebate contracts is no longer a safe bet; instead, they must scrutinize the clinical value of formularies, prior‑authorization criteria, and drug‑mix economics to predict true total cost of ownership.

Specialty drugs continue to dominate pharmacy spend, but the rapid introduction of biosimilars offers a tangible lever for cost reduction. Biosimilars for high‑cost biologics such as Humira and Stelara have already begun eroding market share, and analysts expect a wave of lower‑priced alternatives over the next decade. Employers that embed biosimilar adoption into their PBM contracts can mitigate the impact of declining rebate percentages, especially as the Medicare negotiated‑price framework reduces overall rebate pools. Aligning PBM incentives with generic and biosimilar utilization—through $0 generic copays or targeted chronic‑condition programs—can improve medication adherence while delivering measurable savings.

Finally, the broader economic backdrop—rising overall healthcare inflation and a surge in self‑funded commercial enrollment—pressures plan sponsors to adopt a more disciplined, data‑centric procurement approach. Finance leaders must anticipate lower rebate inflows, focus on net‑cost metrics, and demand transparent fee structures from PBM vendors. Early engagement with brokers, rigorous RFP question design, and continuous monitoring of regulatory developments will empower fiduciaries to select partners that not only meet compliance standards but also drive sustainable, long‑term cost containment.